Compare FARM & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | XLO |
|---|---|---|
| Founded | 1912 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9M | 39.4M |
| IPO Year | 1994 | 2021 |
| Metric | FARM | XLO |
|---|---|---|
| Price | $1.23 | $0.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $2.75 | $2.00 |
| AVG Volume (30 Days) | 329.5K | ★ 441.7K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,281,000.00 | $6,344,000.00 |
| Revenue This Year | $2.66 | $626.78 |
| Revenue Next Year | $2.11 | $79.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.35 | N/A |
| 52 Week Low | $1.22 | $0.46 |
| 52 Week High | $2.38 | $1.18 |
| Indicator | FARM | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 25.70 | 34.34 |
| Support Level | N/A | N/A |
| Resistance Level | $1.59 | $0.74 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 1.52 | 31.21 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.